Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
- Miguel, J.F.S.
- Schlag, R.
- Khuageva, N.K.
- Dimopoulos, M.A.
- Shpilberg, O.
- Kropff, M.
- Spicka, I.
- Petrucci, M.T.
- Palumbo, A.
- Samoilova, O.S.
- Dmoszynska, A.
- Abdulkadyrov, K.M.
- Delforge, M.
- Jiang, B.
- Mateos, M.-V.
- Anderson, K.C.
- Esseltine, D.-L.
- Liu, K.
- Deraedt, W.
- Cakana, A.
- Van De Velde, H.
- Richardson, P.G.
ISSN: 0732-183X, 1527-7755
Argitalpen urtea: 2013
Alea: 31
Zenbakia: 4
Orrialdeak: 448-455
Mota: Artikulua